A Phase I, randomized, double-blind, single ascending dose and multiple ascending dose study to evaluate the safety and pharmacokinetics of GDC-0829 in healthy subjects
Latest Information Update: 27 Feb 2024
At a glance
- Drugs RG 6436 (Primary)
- Indications Urinary tract infections
- Focus Adverse reactions
- Sponsors Roche
Most Recent Events
- 25 Jan 2024 New trial record
- 19 Jan 2024 Status changed from not yet recruiting to recruiting.